skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy

Review

(1116) Views  (486) Full article downloads

Authors: Charlotte Charpentier, Laurence Weiss

Published Date October 2010 Volume 2010:3 Pages 103 - 114
DOI: http://dx.doi.org/10.2147/IDR.S8673

Charlotte Charpentier1, Laurence Weiss2
1Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université Paris-Diderot, Paris, France; 2Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Université Paris Descartes, Paris, France

Abstract: Raltegravir is the first licensed compound in 2007 of the new integrase inhibitor drug class. At the dose of 400 mg twice daily, raltegravir showed a potent antiviral action in antiretroviral-naïve patients when associated with tenofovir and emtricitabine. Raltegravir was also found to be highly active in antiretroviral-experienced patients with virological failure and displaying multiresistant virus, as shown with the BENCHMRK and ANRS 139 TRIO trials. Finally, the use of raltegravir was assessed in the context of a switch strategy in antiretroviral-experienced patients with virological success [human immunodeficiency virus type 1 (HIV-1) RNA below detection limit], highlighting the following mandatory criteria in this strategy: the nucleoside reverse transcriptase inhibitors associated with raltegravir have to be fully active. In the different studies, raltegravir had a favorable safety and tolerability profile. In the clinical situation a switch in virologically suppressed patients receiving a protease inhibitor, an improvement of the lipid profile was observed. Overall, when analyzing the Phase II and III trials together, only a few patients on raltegravir discontinued for adverse events. The development of resistance to raltegravir mainly involved three resistance mutations in integrase gene: Q148H/K/R, N155H, and Y143C/H/R. In conclusion, raltegravir improved the clinical management of HIV-1 infection both in antiretroviral-naïve and in antiretroviral-experienced patients.

Keywords: HIV-1, integrase inhibitors, raltegravir, antiretroviral therapy






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
ABO and rhesus blood group distribution in Kurds
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Effect of long-term treatment with eyedrops for glaucoma on conjunctival bacterial flora
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University